Effect of Probiotics on Cardiometabolic Health

Cardiometabolic Risk Factors Clinical Trial

Official title: An Interventional Study for the Beneficial Effects of Probiotics on Cardio-metabolic Health in Chinese Subjects

Status Completed

Clinical Trial Summary

Atherosclerosis is a major risk factor for cardiovascular diseases. Recently, dysbiosis of gut microbiota has been reported to play an important role in the pathogenesis of atherosclerosis. Animal studies have demonstrated that administration of probiotics help delay the progression of atherosclerosis through several mechanisms. This trial aims to examine its protective effect in humans.

Clinical Trial Description

Atherosclerosis is a major risk factor for cardiovascular diseases. Recently, dysbiosis of gut microbiota has been reported to play an important role in the pathogenesis of atherosclerosis. Animal studies have demonstrated that administration of probiotics help delay the progression of atherosclerosis through several mechanisms such as reduction in endotoxemia, and enhanced production of short-chain fatty acids.

However, whether administration of probiotics also has a protective effect in subjects with metabolic syndrome (MetS), who are at high risk for developing atherosclerosis, remain unknown. ;

Related Conditions & MeSH terms

• Cardiometabolic Risk Factors

• NCT number: NCT05005754
• Study type: Interventional
• Source: Sun Yat-sen University
• Status: Completed
• Phase: N/A
• Start date: September 1, 2021
• Completion date: February 28, 2022